Latest Conference Coverage

The Next Wave of Stroke Care Beyond the Acute Phase: Matthew Schrag, MD, PhD

The associate professor of neurology at Vanderbilt University Medical Center discussed exploring promising opportunities in other phases outside of the acute phase of ischemic stroke. [WATCH TIME: 3 minutes]

Insights on Seizure Therapy and Future Plans in Epilepsy Research: Iryna Leunikava, MSc

The European evidence generation strategy lead for epilepsy and rare syndromes at UCB described some details about further epilepsy research and other explorations in the next few years. [WATCH TIME: 3 minutes]

Enhancing Methodologies for Comprehensive Patient Outcome Analysis in Epilepsy: Derek Ems, MPH, CPHQ

The health economics outcomes research specialist at UCB discussed the need for improved methodologies to have a more accurate analysis of patient outcomes beyond what administrative databases can provide. [WATCH TIME: 2 minutes]

The Urgent Need for Improved Physician-Patient Conversations on SUDEP: Jude Luker, BA (Hons)

The head of Patient Engagement, Epilepsy and Rare Syndromes (Europe) at UCB Pharma discussed the inconsistencies in educational information given to patients with epilepsy, including the knowns of sudden unexpected death. [WATCH TIME: 4 minutes]

Raising Discussion on Gaps in SUDEP Knowledge in Epilepsy Care: Jude Luker, BA (Hons)

The head of Patient Engagement, Epilepsy and Rare Syndromes (Europe) at UCB Pharma discussed findings from a literature review presented at AES 2023 involving conversations about sudden unexpected death in epilepsy. [WATCH TIME: 4 minutes]

Patient-Centered Care to Address Symptoms in Migraine Treatment: Amaal Starling, MD, FAHS, FAAN

A Neurological Perspective on Lessons from the COVID-19 Pandemic in NMOSD: Lorna Galleguillos, MD; Ricardo Alonso MD, MSc

The neuroimmunologist at Clínica Alemana de Santiago and head of the University Center for Multiple Sclerosis at Ramos Mejía Hospital discussed Latin American efforts to understand neuromyelitis optica spectrum disorder during the COVID-19 pandemic. [WATCH TIME: 5 minutes]

Addressing the Unmet Needs of Managing MS Symptoms: Michael Y. Sy, MD, PhD

The associate professor of clinical neurology at University of California, Irvine School of Medicine talked about addressing the critical unmet needs in disability progression among patients with multiple sclerosis. [WATCH TIME: 3 minutes]

Pathing the Next Steps in Alzheimer Disease Research: Heather Snyder, PhD

The vice president of medical and scientific relations at the Alzheimer’s Association discussed where the organization’s efforts are currently invested and the ways to continue momentum in the Alzheimer disease field. [WATCH TIME: 5 minutes]

Neurologist’s Role in Addressing Healthcare Disparities: A. Gordon Smith, MD, FAAN

The professor and chair of neurology at Virginia Commonwealth University discussed how neurologists are urged to take organized action and provide training on healthcare disparities, with a particular focus on race, ethnicity, and financial barriers to access. [WATCH TIME: 2 minutes]

Exploring the Efficacy and Evidence of Efgartigimod as a Potential Therapy for CIDP: Richard Lewis, MD

The professor of neurology at Cedars-Sinai Medical Center talked about efgartigimod as a novel treatment for chronic inflammatory demyelinating polyneuropathy, with the potential of it being a first-line treatment for patients with the condition. [WATCH TIME: 3 minutes]

Preclinical Neuroinflammation Modulation and Neuroprotection With Fosgonimeton in AD: Kevin Church, PhD

Rett Syndrome Symptoms and Quality of Life Improvements Through Trofinetide: Ponni Subbiah, MD, MPH

The chief medical officer of Acadia Pharmaceuticals provided commentary on a caregiver analysis assessing beneficial experiences with trofinetide in patients with Rett syndrome. [WATCH TIME: 4 minutes]

Management of Focal Onset Seizures With Brivaracetam Adjunctive Therapy: Iryna Leunikava, MSc

The European evidence generation strategy lead for epilepsy and rare syndromes at UCB Pharma talked about positive results from observational studies assessing the impact of brivaracetam among patients with focal seizures, which was presented at AES 2023. [WATCH TIME: 5 minutes]

NeuroVoices: Ponni Subbiah, MD, MPH, on the Open-Label LILAC-2 Study of Trofinetide

The senior vice president, global head of medical affairs, and chief medical officer at Acadia Pharmaceutical, gave an overview of LILAC-2, a long-term extension study assessing trofinetide (Daybue), the first approved therapy for Rett syndrome.

Quantifying Impact of Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders

Potential Role of BHV-7000 Among Antiseizure Medications: Irfan Qureshi, MD

The chief medical officer at Biohaven provided context on how BHV-7000 may be used with other antiseizure medications as well as what changes in spectral power tell about the agent. [WATCH TIME: 4 minutes]

Growing Trofinetide’s Long-Term Profile as First Approved Rett Syndrome Therapy: Ponni Subbiah, MD, MPH

The senior vice president, global head of medical affairs, and chief medical officer at Acadia Pharmaceutical, provided an overview of LILAC-2, a long-term, open-label study assessing the treatment benefits of trofinetide (Daybue). [WATCH TIME: 6 minutes]

NeuroVoices: Irfan Qureshi, MD, on the Therapeutic Potential of Antiseizure Agent BHV-7000

The chief medical officer of Biohaven discussed early-stage data supporting the efficacy and safety of BHV-7000, a selective Kv7.2/7.3 potassium channel activator in development for patients with epilepsy.

Understanding the Treatment Benefits of Potassium Channel Activator BHV-7000: Irfan Qureshi, MD

The chief medical officer at Biohaven provided clinical insight on the mechanism of action of BHV-7000, an antiseizure medication, and its supportive phase 1 data. [WATCH TIME: 4 minutes]

Gaining Greater Insights Into Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders: Elizabeth M. Cassidy, MPH

A Real-World Look at the Prolonged Efficacy of Fenfluramine in Dravet Syndrome: Derek Ems, MPH, CPHQ

The health economics outcomes research specialist at UCB talked about a retrospective analysis assessing the persistence of fenfluramine (Fintepla) in Dravet syndrome over 12 months, compared with valproate and levetiracetam. [WATCH TIME: 4 minutes]

Insights From Comprehensive Research on Epilepsy and Cognitive Decline: Ifrah Zawar, MD

The assistant professor of neurology at the University of Virginia talked about findings from a comprehensive study on epilepsy and mild cognitive impairment, which was recently presented at AES 2023. [WATCH TIME: 5 minutes]

Exploring Animal Models to Inform Treatments for Alzheimer-Related Epileptic Activity: Christos Lisgaras, PhD, MSc

The research scientist at NYU Langone Health talked about findings from preclinical data investigating epileptiform activity in mouse models of Alzheimer disease, which were presented at AES 2023. [WATCH TIME: 4 minutes]

Open-Label LILAC-2 Data Demonstrates Trofinetide’s Long-Term Treatment Benefit in Rett Syndrome

Over a 32-week treatment period, patients on trofinetide continued to show improvements on the primary efficacy outcomes of Rett Syndrome Behavior Questionnaire and Clinical Global Impression-Improvement total scores.

Gene Therapy, Innovative Drugs, Surgical Techniques, and the Evolving Landscape of Epilepsy Care: Gregory Krauss, MD

The professor of neurology at Johns Hopkins University School of Medicine talked about the need for education to optimize treatment selection and the continually changing landscape of care for patients with epilepsy. [WATCH TIME: 5 minutes]

Balancing New Medications and Reducing Adverse Effects in Epilepsy Treatment: Louis Ferrari, RPh, MBA

The vice president of medical affairs at SK Life Science talked about findings from a new post-hoc analysis which highlighted the importance of strategically reducing concomitant medications to minimize adverse events of epilepsy treatment. [WATCH TIME: 5 minutes]

Greater Insights into Seizure Causes With Epilepsy Genetic Testing in Adults: Yi Li, MD, PhD

The clinical assistant professor of neurology at Stanford University talked about findings from a study on genetic testing in adults with epilepsy and the importance of access to genetic testing for this patient population. [WATCH TIME: 7 minutes]

Ketogenic Diet Effective and Tolerable to Reduce Seizures in Infants

Although a small-scale study, most infants had a positive response to ketogenic diet, with even greater effects seen in those with Ohtahara syndrome.

Emphasizing Patient Conversations and Treatment Opportunities for Seizure Management: Danielle Becker, MD, MS, FAES

The division director of epilepsy and associate professor of neurology at The Ohio State University Wexner Medical Center talked about the impact of ongoing seizures in patients with drug-resistant epilepsy and the importance of education for emerging opportunities in epilepsy care. [WATCH TIME: 3 minutes]